Premium
Epstein‐Barr virus reactivation in a patient treated with anti‐thymocyte globulin for severe aplastic anemia
Author(s) -
Calistri Elisabetta,
Tiribelli Mario,
Battista Marta,
Michelutti Angela,
Corbellino Mario,
Viale Pierluigi,
Fanin Renato,
Damiani Daniela
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20560
Subject(s) - anti thymocyte globulin , aplastic anemia , medicine , hematopoietic stem cell transplantation , immunology , mononucleosis , complication , immune system , anemia , incidence (geometry) , globulin , virus , transplantation , gastroenterology , bone marrow , physics , optics
Epstein‐Barr virus (EBV) infection and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Therapy with anti‐thymocyte globulin (ATG) is associated with higher incidence of EBV‐related disease in HSCT patients, but this risk is not documented in patients receiving ATG for severe aplastic anemia (SAA). We describe the case of a patient who developed an EBV infection, with the clinical features of an infectious mononucleosis, after immune suppression with cyclosporine and two courses of ATG for SAA. Am. J. Hematol. 81:355–357, 2006. © 2006 Wiley‐Liss, Inc.